- Current report filing (8-K)
December 08 2011 - 3:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of Earliest Event Reported): December 8, 2011 (December 6, 2011)
Gilead Sciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-19731
|
|
94-3047598
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
333 Lakeside Drive, Foster City,
California
|
|
94404
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (650) 574-3000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
On December 6, 2011, Gilead Sciences, Inc. (the Company) entered into an underwriting agreement (the Underwriting Agreement) with Merrill Lynch, Pierce, Fenner &
Smith Incorporated and Barclays Capital Inc., as representatives of the several underwriters listed in Schedule 1 thereto, relating to the sale by the Company of (a) $750.0 million aggregate principal amount of the Companys 2.40% Senior
Notes due 2014, (b) $700.0 million aggregate principal amount of the Companys 3.05% Senior Notes due 2016, (c) $1.25 billion aggregate principal amount of the Companys 4.40% Senior Notes due 2021 and (d) $1.0 billion
aggregate principal amount of the Companys 5.65% Senior Notes due 2041.
Certain of the underwriters and their affiliates have in the
past provided, an may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with the Company or its affiliates. They have received, or may in the future receive, customary fees and commissions
for these transactions.
In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or
hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and
securities activities may involve securities and/or instruments of the Company or its affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of the
Companys securities or financial or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.
The Underwriting Agreement is filed herewith as Exhibit 1.1. The description of the Underwriting Agreement herein is qualified by reference thereto.
Item 9.01.
|
Financial Statements and Exhibits.
|
The
Underwriting Agreement contains representations and warranties by each of the parties thereto. These representations and warranties have been made solely for the benefit of the other party or parties to the Underwriting Agreement and:
|
|
|
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one or more of the parties if
those statements prove to be inaccurate;
|
|
|
|
may have been qualified by disclosures that were made to the other party or parties in connection with the negotiation of the Underwriting Agreement,
which disclosures are not necessarily reflected in such agreement;
|
|
|
|
may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
|
|
|
|
were made only as of the date of the Underwriting Agreement or such other date or dates as may be specified in such agreement and are subject to more
recent developments.
|
Accordingly, these representations and warranties may not describe the actual state of affairs as of
the date they were made or at any other time. The Company acknowledges that, notwithstanding the inclusion of the foregoing general disclaimer, it is responsible for considering whether additional specific disclosures of material information
regarding material contractual provisions are required to make the statements in this report not misleading.
Additional information about the
Company may be found elsewhere in this report and the Companys other public filings, which are available without charge through the Securities and Exchange Commissions website at http://www.sec.gov.
The following exhibit is filed as part of this Current Report on Form 8-K:
|
|
|
Exhibit No.
|
|
Description
|
|
|
1.1
|
|
Underwriting Agreement, dated December 6, 2011, among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital Inc., as representatives of the
several underwriters listed in Schedule 1 thereto
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
GILEAD SCIENCES, INC.
|
|
|
(Registrant)
|
|
|
By:
|
|
/s/ Robin L. Washington
|
|
|
Name: Robin L. Washington
|
|
|
Title: Senior Vice President and Chief Financial Officer
|
Dated: December 8, 2011
EXHIBIT LIST
|
|
|
Exhibit No.
|
|
Description
|
|
|
1.1
|
|
Underwriting Agreement, dated December 6, 2011, among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital Inc., as representatives of the
several underwriters listed in Schedule 1 thereto
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024